Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
Body unavailable. Use the original source.
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.